Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection. (Q54514050)

30 May 2018

title

Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection. (English)

1 reference

30 May 2018

author name string

Xinchun Chen

1

1 reference

30 May 2018

Meizhong Li

2

1 reference

30 May 2018

Xiaohua Le

3

1 reference

30 May 2018

Weimin Ma

4

1 reference

30 May 2018

Boping Zhou

5

1 reference

30 May 2018

language of work or name

English

0 references

publication date

1 January 2004

1 reference

30 May 2018

published in

Vaccine

1 reference

30 May 2018

volume

22

1 reference

30 May 2018

issue

3-4

1 reference

30 May 2018

page(s)

439-446

1 reference

30 May 2018

Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.014

Treatment of chronic hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.014

Specific vaccine therapy in chronic hepatitis B infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.014

Immune therapy of hepatitis B virus chronic infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.014

Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.014

Peptide vaccines against hepatitis B virus: from animal model to human studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.014

A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.014

Molecular features of the hepatitis B virus nucleocapsid T-cell epitope 18-27: interaction with HLA and T-cell receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.014

Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.014

Presentation and Immunogenicity of Viral Epitopes on the Surface of Hybrid Hepatitis B Virus Core Particles Produced in Bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.014

T-cell and antibody response characterisation of a new recombinant pre-S1, pre-S2 and SHBs antigen-containing hepatitis B vaccine; demonstration of superior anti-SHBs antibody induction in responder mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.014

Properties of modified hepatitis B virus surface antigen particles carrying preS epitopes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.014

The preS1 antigen of hepatitis B virus is highly immunogenic at the T cell level in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.014

T- and B-cell recognition of hepatitis B viral antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.014

Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.014

HBV infection of cell culture: evidence for multivalent and cooperative attachment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.014

Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.014

Native display of complete foreign protein domains on the surface of hepatitis B virus capsids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.014

Expression and characterization of chimeric hepatitis B surface antigen particles carrying preS epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.014

CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.014

Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.014

Characterization of CD8+ cytotoxic T-lymphocyte responses after genetic immunization with retrovirus vectors expressing different forms of the hepatitis B virus core and e antigens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.014

Hepatitis B virus nucleocapsid assembly: primary structure requirements in the core protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.014

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2003.07.014

1 reference

30 May 2018

PubMed ID

14670326

1 reference

30 May 2018